Market Overview:
The global antiretroviral drug market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing incidence of HIV/AIDS, rising demand for combination therapies, and growing number of generic antiretroviral drugs. Based on type, the global antiretroviral drug market is segmented into multi-class drugs combination, NRTI (nucleoside reverse transcriptase inhibitors), NNRTI (non-nucleoside reverse transcriptase inhibitors), protease inhibitors, and other types. The multi-class drugs combination segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to increasing demand for these drugs due to their better efficacy and safety profile as compared with other types of antiretroviral drugs. Based on application, the global antiretroviral drug market is segmented into hospitals, pharmaceutical companies, and other applications. The hospitals segment is expected to grow at a higher CAGR during the forecast period owing to rising incidence of HIV/AIDS cases across the globe.
Product Definition:
An antiretroviral (ARV) is a drug used to treat HIV/AIDS. ARVs work by preventing the virus from replicating in the body, which helps keep HIV levels low and delays or prevents AIDS-related illnesses.
Multi-Class Drugs Combination:
Multi-class combination drugs are a type of antiretroviral drug treatment used to reduce the amount of virus in the body. The multi-class combination drugs include at least 2 antiRetroviral agents that work together to prevent the infection from spreading and/or disease progression.
NRTI:
NRTIs are a class of anti-retroviral drugs that inhibit reverse transcriptase and protease enzymes. NRTIs include Efavirenz, Delavirdine, Tenofovir, and Empagliflozin. The drug class is majorly used in the treatment of HIV infection but some drugs like Delavirdine also have use against other retrovirus infections like HTLV-1 & 2 & SIV.
Application Insights:
The hospital application segment dominated the global market in 2017. The segment is expected to witness a CAGR of XX% over the forecast period owing to an increase in patients suffering from HIV and AIDS, which has resulted in an increased demand for antiretroviral drugs. According to UNAIDS, globally around 37 million people were living with HIV/AIDS and about 1.8 million died due to AIDS-related causes in 2016.
Pharmaceutical companies are anticipated to be the fastest growing application segment over the forecast period owing to high R&D investments coupled with increasing government initiatives that have led towards commercializing new drugs for treating various diseases including HIV infection (1). For instance, according these guidelines GlaxoSmithKline will invest USD 4 billion annually by 2020 on researching into innovative medicines across different disease areas such as cancer & immunodeficiency disorders (2).
Regional Analysis:
The global antiretroviral drug market is dominated by the U.S., with a revenue share of over 80% in 2016. The country has been experiencing an increase in the number of people infected with HIV since the launch of combination therapy, which has led to an increase in demand for these drugs globally. Moreover, increasing government funding and healthcare expenditure coupled with high R&D investment by pharmaceutical companies are some factors that have contributed to this dominance.
However, Asia Pacific is expected to be one of the fastest growing regions due to rising prevalence levels and improving access & coverage issues pertaining to treatment & care initiatives taken up by various governments across countries such as India.
Growth Factors:
- Increasing incidence of HIV/AIDS: The global incidence of HIV is on the rise, with an estimated 36.7 million people living with the virus in 2016. This is expected to drive demand for antiretroviral drugs in the coming years.
- Growing awareness about HIV and its treatment: There is a growing awareness among people about HIV and its treatment options, which is likely to boost demand for antiretroviral drugs in the near future.
- Technological advancements: The development of new and more effective antiretroviral drugs has helped improve patient outcomes, thus driving market growth.
- Rising prevalence of co-infections: The increasing prevalence of co-infections such as tuberculosis (TB) and hepatitis C (HCV) is leading to an increase in demand for combination therapies that include multiple antiretrovirals, thereby propelling market growth further.
Scope Of The Report
Report Attributes
Report Details
Report Title
Antiretroviral Drug Market Research Report
By Type
Multi-Class Drugs Combination, NRTI, NNRTI, Protease Inhibitors, Other
By Application
Hospital, Pharmaceutical Companies, Other
By Companies
Gilead Sciences, ViiV Healthcare, Bristol-Myer Squibb, AbbVie, Boehringer-Ingelheim, Johnson and Johnson, Merck, CIPLA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Antiretroviral Drug Market Report Segments:
The global Antiretroviral Drug market is segmented on the basis of:
Types
Multi-Class Drugs Combination, NRTI, NNRTI, Protease Inhibitors, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmaceutical Companies, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gilead Sciences
- ViiV Healthcare
- Bristol-Myer Squibb
- AbbVie
- Boehringer-Ingelheim
- Johnson and Johnson
- Merck
- CIPLA
Highlights of The Antiretroviral Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Multi-Class Drugs Combination
- NRTI
- NNRTI
- Protease Inhibitors
- Other
- By Application:
- Hospital
- Pharmaceutical Companies
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Antiretroviral Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Antiretroviral drugs are medications used to treat HIV. These drugs work by blocking the replication of the virus.
Some of the major companies in the antiretroviral drug market are Gilead Sciences, ViiV Healthcare, Bristol-Myer Squibb, AbbVie, Boehringer-Ingelheim, Johnson and Johnson, Merck, CIPLA.
The antiretroviral drug market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Antiretroviral Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Antiretroviral Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Antiretroviral Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Antiretroviral Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Antiretroviral Drug Market Size & Forecast, 2018-2028
4.5.1 Antiretroviral Drug Market Size and Y-o-Y Growth
4.5.2 Antiretroviral Drug Market Absolute $ Opportunity
Chapter 5 Global Antiretroviral Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Antiretroviral Drug Market Size Forecast by Type
5.2.1 Multi-Class Drugs Combination
5.2.2 NRTI
5.2.3 NNRTI
5.2.4 Protease Inhibitors
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Antiretroviral Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Antiretroviral Drug Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmaceutical Companies
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Antiretroviral Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Antiretroviral Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Antiretroviral Drug Analysis and Forecast
9.1 Introduction
9.2 North America Antiretroviral Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Antiretroviral Drug Market Size Forecast by Type
9.6.1 Multi-Class Drugs Combination
9.6.2 NRTI
9.6.3 NNRTI
9.6.4 Protease Inhibitors
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Antiretroviral Drug Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmaceutical Companies
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Antiretroviral Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Antiretroviral Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Antiretroviral Drug Market Size Forecast by Type
10.6.1 Multi-Class Drugs Combination
10.6.2 NRTI
10.6.3 NNRTI
10.6.4 Protease Inhibitors
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Antiretroviral Drug Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmaceutical Companies
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Antiretroviral Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Antiretroviral Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Antiretroviral Drug Market Size Forecast by Type
11.6.1 Multi-Class Drugs Combination
11.6.2 NRTI
11.6.3 NNRTI
11.6.4 Protease Inhibitors
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Antiretroviral Drug Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmaceutical Companies
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Antiretroviral Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Antiretroviral Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Antiretroviral Drug Market Size Forecast by Type
12.6.1 Multi-Class Drugs Combination
12.6.2 NRTI
12.6.3 NNRTI
12.6.4 Protease Inhibitors
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Antiretroviral Drug Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmaceutical Companies
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Antiretroviral Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Antiretroviral Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Antiretroviral Drug Market Size Forecast by Type
13.6.1 Multi-Class Drugs Combination
13.6.2 NRTI
13.6.3 NNRTI
13.6.4 Protease Inhibitors
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Antiretroviral Drug Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmaceutical Companies
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Antiretroviral Drug Market: Competitive Dashboard
14.2 Global Antiretroviral Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Gilead Sciences
14.3.2 ViiV Healthcare
14.3.3 Bristol-Myer Squibb
14.3.4 AbbVie
14.3.5 Boehringer-Ingelheim
14.3.6 Johnson and Johnson
14.3.7 Merck
14.3.8 CIPLA
